Comparison of metformin and livergol in patients with non-alcoholic fatty liver disease

Comparison of the effect of metformin and livergol in liver enzymes in patients with non-alcoholic fatty liver

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210514051287N1

Enrollment

Registered

2022-03-04

Start date

2022-04-09

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: First, the studied variables are evaluated before the intervention, then this group will receive metformin (N,N-dimethylbiguanide) with the chemical composition of C4H11N5 and a dose o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Non-alcoholic fatty liver based on ultrasound increase liver enzymes above normal

Exclusion criteria

Exclusion criteria: People with suspected fatty liver disease according to history in terms of alcohol consumption, the presence of other concomitant diseases such as hepatitis B, C, insulin use Pregnancy Taking effective LFT drugs

Design outcomes

Primary

Measure	Time frame
TG. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;Ch. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;LDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;HDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;BS. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;SGPT. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;SGOT. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;BMI. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on measurement and calculation.;Degree of liver steatosis. Timepoint: Before intervention and 2 months after intervention. Method of measurement: According to the pathology report.	—

Measure

Time frame

TG. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;Ch. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;LDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;HDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;BS. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;SGPT. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;SGOT. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on turbidometric tests.;BMI. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Based on measurement and calculation.;Degree of liver steatosis. Timepoint: Before intervention and 2 months after intervention. Method of measurement: According to the pathology report.

—

Secondary

Measure	Time frame
Patient recovery rate. Timepoint: Two months later the intervention. Method of measurement: Based on examination and tests.;Side effects of treatment. Timepoint: Two months later the intervention. Method of measurement: Based on examination and tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTahereh Mahdavi

Qazvin University of Medical Sciences

dr.amirrezakhazzaei@gmail.com+98 28 3379 0611

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026